Cargando…

One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug

HIGHLIGHTS: Many AD target combinations are being explored for multi-target drug design. New databases and models increase the potential of computational drug design. Liraglutide and other antidiabetics are strong candidates for repurposing to AD. Donecopride a dual 5-HT/AChE inhibitor shows promise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hughes, Rebecca E., Nikolic, Katarina, Ramsay, Rona R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4842778/ https://www.ncbi.nlm.nih.gov/pubmed/27199640 http://dx.doi.org/10.3389/fnins.2016.00177

Ejemplares similares

Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity
por: Szabó, Zoltán, et al.
Publicado: (2021)

Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease
por: Unzeta, Mercedes, et al.
Publicado: (2016)

Editorial: Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases
por: Ramsay, Rona R., et al.
Publicado: (2017)

ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy
por: Marco-Contelles, José, et al.
Publicado: (2016)

A perspective on multi-target drug discovery and design for complex diseases
por: Ramsay, Rona R., et al.
Publicado: (2018)

Editorial: Pulmonary fibrosis: One manifestation, various diseases
por: Ruaro, Barbara, et al.
Publicado: (2022)

The microbial one-hit wonder
por: Rusconi, Brigida A., et al.
Publicado: (2021)

One, Two, Three: Polycomb Proteins Hit All Dimensions of Gene Regulation
por: del Prete, Stefania, et al.
Publicado: (2015)

Multiple Targeting Approaches on Histamine H(3) Receptor Antagonists
por: Khanfar, Mohammad A., et al.
Publicado: (2016)

One-hit wonders of genomic instability
por: Strunnikov, Alexander V
Publicado: (2010)

One for All and All in One?
por: Folkenroth-Hess, Sharon
Publicado: (2021)

Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target?
por: Jovanovic, Mirjana R., et al.
Publicado: (2017)

Glutathione S-conjugates as prodrugs to target drug-resistant tumors
por: Ramsay, Emma E., et al.
Publicado: (2014)

A Novel 5-HT(1B) Receptor Agonist of Herbal Compounds and One of the Therapeutic Uses for Alzheimer’s Disease
por: Yang, Yang, et al.
Publicado: (2021)

Bat pathogens hit the road: But which one?
por: Joffrin, Léa, et al.
Publicado: (2018)

When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?
por: Baird, Anne-Marie, et al.
Publicado: (2019)

The microbiome-product colibactin hits unique cellular targets mediating host–microbe interaction
por: Mousa, Walaa K.
Publicado: (2022)

Face masks: all for one and one for all
por: The Lancet Respiratory Medicine
Publicado: (2021)

A Pharmacoinformatics Analysis of Artemisinin Targets and de novo Design of Hits for Treating Ulcerative Colitis
por: Tian, Rui, et al.
Publicado: (2022)

Three Is Better than One: An Improved Multiple-Hit Model of Primary Graft Dysfunction
por: Smirnova, Natalia F., et al.
Publicado: (2019)

A Systematic Strategy for Discovering a Therapeutic Drug for Alzheimer’s Disease and Its Target Molecule
por: Yang, Zhiyou, et al.
Publicado: (2017)

Modeling and Targeting Alzheimer’s Disease With Organoids
por: Papaspyropoulos, Angelos, et al.
Publicado: (2020)

Therapeutic Effects of Natural Drugs on Alzheimer’s Disease
por: Ma, Yuan, et al.
Publicado: (2019)

Tumour Suppressor Genes—One Hit Can Be Enough
por: Hohenstein, Peter
Publicado: (2004)

Anti-Cancer Vaccines — A One-Hit Wonder?
por: Liu, Justin K.H.
Publicado: (2014)

Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All
por: Sudhakar, Padhmanand, et al.
Publicado: (2022)

Target Identification of Mycobacterium tuberculosis Phenotypic Hits Using a Concerted Chemogenomic, Biophysical, and Structural Approach
por: Mugumbate, Grace, et al.
Publicado: (2017)

Alzheimer’s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?
por: Melchiorri, Daniela, et al.
Publicado: (2023)

One-Hit Wonders and 2-Hit Tubers: A Second-Hit to TSC2 Causes Tuber-Like Cells in Spheroids
por: Goswami, Sonal, et al.
Publicado: (2019)

Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT
por: Declercq, Lieven D., et al.
Publicado: (2016)

Therapeutic Potential of Astrocyte Purinergic Signalling in Epilepsy and Multiple Sclerosis
por: Nobili, Paola, et al.
Publicado: (2022)

Iron dyshomeostasis and ferroptosis in Alzheimer’s disease: Molecular mechanisms of cell death and novel therapeutic drugs and targets for AD
por: Zhang, Yuan, et al.
Publicado: (2022)

One for all or all for one? An integrative review of research on frequent callers
por: Skogevall, S., et al.
Publicado: (2022)

One for all
por: Odom, Duncan T
Publicado: (2016)

Not One for All
por: Cho, Hae-Wol, et al.
Publicado: (2017)

Segmental neurofibromatosis type 2: discriminating two hit from four hit in a patient presenting multiple schwannomas confined to one limb
por: Castellanos, Elisabeth, et al.
Publicado: (2015)

Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies
por: Nikolic, Katarina, et al.
Publicado: (2016)

All for one and one for all—new multifunctional sternal retractor
por: Fleissner, Felix, et al.
Publicado: (2020)

Targeting Renin–Angiotensin System Against Alzheimer’s Disease
por: Gebre, Abadi Kahsu, et al.
Publicado: (2018)

Targeting Synaptic Plasticity in Experimental Models of Alzheimer’s Disease
por: Mango, Dalila, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_urp356scf4vvi5f15plpbep61g